Isaac Barchas - 10 Aug 2026 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Director
Issuer ticker: IMNM
Reported as of: 10 Aug 2026
Net transaction value: -$2,198,910
SEC form: 4
Accepted by SEC: 12 Aug 2026, 17:47:01 UTC
Prior SEC filing: 10 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Isaac Barchas filed Form 4 for Immunome Inc. (IMNM) on 12 Aug 2026.

Key facts

This page summarizes Isaac Barchas's Form 4 filing for Immunome Inc. (IMNM).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 17:47.

Change

Previous filing in this sequence was filed on 10 Aug 2026.
Current net transaction value: -$2,198,910.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808343 Primary reporting owner

Barchas Isaac

Relationship: Director
Address: C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNM transaction

Common Stock

Sale

Transaction value: $263,959
Shares: -10,125
Change %: -14%
Price: $26.07
Shares after: 62,291
Date: 10 Aug 2026
Ownership: See footnote
Footnotes: F1, F2, F3

IMNM transaction

Common Stock

Sale

Transaction value: $1,633,893
Shares: -62,291
Change %: -100%
Price: $26.23
Shares after: 0
Date: 11 Aug 2026
Ownership: See footnote
Footnotes: F1, F3, F4

IMNM transaction

Common Stock

Sale

Transaction value: $301,058
Shares: -11,048
Change %: -11%
Price: $27.25
Shares after: 92,211
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

Footnote F2

The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

Footnote F4

The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F5

The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.